Avance Life Sciences - Company finances
|
EUR
|
2023
From: 2023-11-24
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | - | 59,000 | 3,000 |
| Profit before tax | 0 | 993 | -2,572 |
| Net profit | 0 | 830 | -2,572 |
| Equity | 1,000 | 1,830 | -805 |
| Liabilities | 20 | 1,157 | 1,123 |
| Non-current assets | 0 | 0 | 0 |
| Current assets | 1,020 | 2,987 | 318 |
| Total assets | 1,020 | 2,987 | 318 |
|
Taxes paid
|
|||
| STI taxes | - | 10,767 | 454 |
|
Financial indicators
|
|||
| Revenue change y/y | - | - | -94.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 27.8% | -808.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 45.4% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 1.4% | -85.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 1.7% | -85.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.6 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 29,500 | 1,500 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Avance Life Sciences - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-19 | 2026-08-02 | 0.07 |
| 2026-07-16 | 2026-07-17 | 0.07 |
| 2026-06-16 | 2026-06-30 | 0.07 |
| 2026-05-17 | 2026-05-27 | 0.08 |
| 2026-05-03 | 2026-05-03 | 0.08 |
| 2026-04-24 | 2026-04-29 | 0.08 |
| 2026-02-18 | 2026-03-01 | 24.14 |
Avance Life Sciences - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Avance Life Sciences, UAB (company code 306633019) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In the latest financial year, 2025, the company generated revenue of €3.0K and recorded a net loss of €2.6K, resulting in a negative profit margin of -85.7%. Revenue fell by 94.9% year on year from €59.0K in 2024, when the company posted a net profit of €830. The 2025 balance sheet was very small, with total assets of €318, equity of -€805 and liabilities of €1.1K. Compared with 2024, when assets stood at €3.0K and equity at €1.8K, the financial position weakened materially and moved into negative equity. Ratios should be read with caution because they are affected by the very small and negative equity base. Asset turnover was 9.43x, indicating high revenue relative to the asset base. Revenue per employee was €1.5K in 2025, while profit per employee was negative.